Last updated September 12, 2026
Key finding
Dapagliflozin was associated with greater reductions in FPG.
This study evaluated the effects of dapagliflozin in kidney transplant recipients with post-transplant diabetes mellitus. It found that dapagliflozin significantly reduced fasting plasma glucose and improved other metabolic markers compared to standard care.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of dapagliflozin in kidney transplant recipients with post-transplant diabetes mellitus. It found that dapagliflozin significantly reduced fasting plasma glucose and improved other metabolic markers compared to standard care.
These findings are important as they suggest that dapagliflozin may provide additional benefits for kidney transplant recipients struggling with diabetes, potentially leading to better management of blood sugar levels and kidney health. This could help improve patient outcomes and reduce complications associated with diabetes in this vulnerable population.
No significant changes in hemoglobin A1c or eGFR were noted. The study may have limited generalizability due to the specific population. The sample size and duration of the study may limit the robustness of the findings.
Published in
Publication details and source links for this paper.
Lu L, Jinghui L, Junwei Z, et al. Dapagliflozin in Kidney Transplant Recipients with Post-Transplant Diabetes Mellitus: A Randomized Controlled Trial. Kidney International Reports. 2026;11(7):106559. doi:10.1016/j.ekir.2026.106559
Dapagliflozin reduced fasting plasma glucose by -1.02 mmol/l (p = 0.008).
Dapagliflozin improved serum uric acid levels by -41.84 µmol/l.
Dapagliflozin enhanced urinary albumin-to-creatinine ratio by -0.74 mg/mmol.
No significant differences in hemoglobin A1c or eGFR were observed.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dapagliflozin 10 mg/day and Estimated glomerular filtration rate, Fasting Plasma Glucose (FPG), Hemoglobin A1c (HbA1c) with AST, and 4 more.
This study contributes evidence to
Primary intervention
Dapagliflozin 10 mg/day
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
7
Evidence pairs
886
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Dapagliflozin 10 mg/day → Estimated glomerular filtration rate
Dapagliflozin 10 mg/day → Estimated glomerular filtration rate
Dapagliflozin 10 mg/day → Fasting Plasma Glucose (FPG)
Dapagliflozin 10 mg/day → Fasting Plasma Glucose (FPG)
Dapagliflozin 10 mg/day → Hemoglobin A1c (HbA1c) with AST
Dapagliflozin 10 mg/day → Hemoglobin A1c (HbA1c) with AST
Dapagliflozin 10 mg/day → Renal Resistive Index (RRI)
Dapagliflozin 10 mg/day → Renal Resistive Index (RRI)
Dapagliflozin 10 mg/day → Serious adverse events
Dapagliflozin 10 mg/day → Serious adverse events
Dapagliflozin 10 mg/day → Urinary albumin-to-creatinine ratio
Dapagliflozin 10 mg/day → Urinary albumin-to-creatinine ratio
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Dapagliflozin 10 mg/day and Fasting Glucose, Dapagliflozin 10 mg/day and Kidney Function.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on Dapagliflozin 10 mg/day
Contributes to Dapagliflozin 10 mg/day evidence base.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies measuring Kidney Function
Measures Kidney Function as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Dapagliflozin 10 mg/day appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Dapagliflozin 10 mg/day appears to improve renal resistive index (RRI).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Renal Resistive Index (RRI)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Dapagliflozin 10 mg/day appears to improve serum uric acid.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Serum Uric Acid
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Dapagliflozin 10 mg/day for estimated glomerular filtration rate.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Estimated glomerular filtration rate
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
